At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Alisertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating Alisertib for Diffuse Large B-cell Lymphoma and 4 related conditions. Completed, enrolled 48 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma, Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartFeb 2009
Primary CompletionJan 2011
Study CompletionFeb 2013
TodayJul 2026
First PostedDec 12, 2008
Enrollment StartFeb 10, 2009
Primary CompletionJan 4, 2011
Study CompletionFeb 13, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.6 years ago
Interventions
Alisertibdrug
Alisertib capsules